Our Commitment to You:

As the world’s leading provider of genomic-based diagnostic tests, Exact Sciences is committed to improving cancer treatment decisions and optimizing cancer care. We believe you should have access to the information you need to make confident, informed decisions about your treatment options.

To ensure you can focus on your health, Exact Sciences created the Genomic Access Program (GAP), which helps eligible patients determine payment options. To learn more, contact our Customer Service group by phone at 888-662-6897, option 2.

Exact Science’s Precision Oncology portfolio includes tests that apply advanced genomic science to reveal the unique biology of your individual tumor to help you and your doctor determine the best treatment or management option for you.

How the Genomic Access Program (GAP) Works:

If you have private health insurance, Exact Sciences bills your insurance once testing is complete and we confirm your insurance coverage.1

If your insurance denies payment, Exact Sciences will pursue appeals on your behalf where appropriate, and if appeal options are available. This process may take several months and you may receive a denial letter from your insurance company.2

You may receive multiple Explanation of Benefits (EOB) from your insurance. You will only receive a bill that looks like the one shown on the reverse, if payment is required after your claim is fully processed. Contact the GAP support team to discuss payment terms and financial assistance that may be available to you.3

If you are insured through government health coverage programs, Exact Sciences bills your insurance once testing is complete.

If your insurance denies payment, contact the GAP support team to determine what options might be available to you.3

If you don’t have insurance, the GAP support team will help you determine your eligibility for financial assistance and explore the best options available to you.3

1. If your insurance coverage was not in effect on the date of service, we will follow up with you for updated insurance information. If you do not have updated insurance, you will be billed for the cost of the test. You may be eligible for Financial Assistance and payment terms.

2. In some cases, consent to appeal is required. If your insurance company requires consent for Exact Sciences to appeal on your behalf, we will contact you. It is important to sign and return consent forms as soon as possible to allow timely appeals in case the claim is denied.


Contact us to learn more about how GAP may be able to help you at: 1-888-662-6897, option 2

Please note that Exact Sciences is currently unable to accept orders for the Oncomap ExTra test for patients whose specimen was collected in or originated from the state of New York. We are working diligently to obtain the appropriate New York State Department of Health (NYSDOH) permit so that we are able to accept such orders in the future.
You may receive multiple EOBs from your insurance and will receive a bill that looks like the one below if payment is required after the claim is fully processed. Do not make a payment until then.

**SAMPLE BILL**

**NOT A BILL**

1. If your insurance coverage was not in effect on the date of service, we will follow up with you for updated insurance information. If you do not have updated insurance, you will be billed for the cost of the test. You may be eligible for Financial Assistance and payment terms.

2. Consent form allows Exact Sciences to appeal if the claim is denied. Please send to odxclaimsupport@genomichealth.com or mail to: PO Box 742415, Los Angeles, CA 90074-2415

3. Please call your insurance if you have specific questions regarding your insurance coverage.

---

**About Exact Sciences**

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps people get the answers they need to make more informed decisions across the cancer continuum. Building on the success of the Cologuard®, Oncotype® and Oncomap™ tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Through an innovative, rigorous approach, and with the support of visionary collaborators, we’re helping advance the fight against cancer.